Transforming lives with pioneering ocular gene therapy
Beacon Therapeutics is an ophthalmic gene therapy company founded to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
CEO Lance Baldo
Advent Contact Dominic Schmidt
Private Companies
Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer
Press Release. CEO Dave Fellows named non-Executive Chairman of the Board Executive appointments follow $170 million Series B fundraise London, UK and Cambridge, Mass., July 24, 2024 – Beacon…
Read More